- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Bang for the Buck: How Health Care Innovation Affects Life Expectancy and Patient Well-Being
During a webinar, experts discussed where health care has improved life expectancy and the relationship between cost and relative contribution that each area makes to life improvement and expectancy.
During a 60-minute discussion, the speakers on The American Journal of Managed Care® webinar "Bang for the Buck: How Health Care Innovation Affects Life Expectancy and Patient Well-Being" highlighted where health care has improved life expectancy and which areas (public health, drugs, hospital care, surgery, devices, etc.) have contributed the most.
The speakers framed the discussion around 3 papers published in the last year abut the connection between health care spending and value creation.
Robert W. Dubois, MD, PhD, interim president and CEO of the National Pharmaceutical Council, moderated the discussion with:
- Mariam Alboustani, RPh, clinical pharmacy manager, Medicare Pharmacy Services, Blue Cross Blue Shield of Michigan
- Jason Buxbaum, MHSA, PhD candidate, program in health policy, Harvard University
- Michael Ciarametaro, MBA, vice president of research, National Pharmaceutical Council
- David Cutler, PhD, Otto Eckstein Professor of Applied Economics, Harvard University
Let us know what you thought of the webinar and take our short survey.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
